Affimed N.V. announced that Angus Smith has notified the company of his intention to resign as the Chief Financial Officer of the Company effective as of December 31, 2023. Mr. Smith plans to become the chief financial officer of a Boston-based biotech company. The Company has commenced a process with an executive search firm for a new permanent CFO.

As part of the transition plan, the Company announced that the experienced financial and biotechnology industry executive Harry Welten will assume the operating responsibilities of interim CFO as of December 31, 2023 and will continue to operate in that capacity until a permanent successor has been appointed. Mr. Welten has more than 20 years of U.S. and European executive management experience in the biotechnology, pharmaceutical and banking industries, and has served as CFO for several publicly traded biotechnology companies, including Kuros Biosciences AG (formerly Cytos Biotechnology AG), Horizon Pharma AG (formerly Nitec Pharma AG) and Arpida AG.